Adenocarcinoma of the lung other diagnostic studies: Difference between revisions
Shanshan Cen (talk | contribs) No edit summary |
Shanshan Cen (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Adenocarcinoma of the lung}} | {{Adenocarcinoma of the lung}} | ||
{{CMG}}; {{AE}} {{SC}} | {{CMG}}; {{AE}} {{SC}} | ||
===Molecular Test | ==Overview== | ||
==Molecular Test== | |||
Molecular tests include epidermal growth factor receptor ([[EGFR]]) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present. | Molecular tests include epidermal growth factor receptor ([[EGFR]]) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present. | ||
==References== | ==References== | ||
Revision as of 21:54, 4 January 2016
|
Adenocarcinoma of the Lung Microchapters |
|
Differentiating Adenocarcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Adenocarcinoma of the lung other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Adenocarcinoma of the lung other diagnostic studies |
|
Adenocarcinoma of the lung other diagnostic studies in the news |
|
Blogs on Adenocarcinoma of the lung other diagnostic studies |
|
Risk calculators and risk factors for Adenocarcinoma of the lung other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Overview
Molecular Test
Molecular tests include epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present.